Palyatif bakım, yaşamı tehdit eden fiziksel, psikolojik, sosyal ya da ruhsal hastalıklarla ilgili zorluklarla karşılaşan hastaların ve ailelerinin yaşam kalitesini artırmayı hedeflemektedir. Palyatif bakım hastaları ileri yaş, hareket kabiliyetinde azalma ve malign hastalık dâhil eş zamanlı kronik hastalık varlığına sahip hasta popülasyonundan oluştuğu için venöz tromboembolizm riski yönünden takip edilmelidir. Venöz tromboembolizm riskini azaltmak amacı ile tromboprofilaksi tedavisi uygulanmaktadır. Ancak tromboprofilaksi alacak hastaların belirlenmesi, venöz tromboembolizmin teşhisi, tedavisi ve tedavi süresi palyatif bakım hastalarında venöz tromboembolizm yönetiminin zorluklarını oluşturmaktadır. Venöz tromboembolizm yönetimine ait kılavuzlar daha çok onkoloji hastalarına yönelik olup, palyatif bakım hastalarında venöz tromboembolizmin yönetimine yer veren kılavuzlar oldukça sınırlıdır. Bu çalışmanın amacı, güncel kılavuzlar incelenerek, palyatif bakım servisinde yatma potansiyeli olan hastalarda tromboprofilaksi tedavisinin gerekliliğini ve hangi ajanların kullanımının uygun olduğunu özetlemektir. Kılavuzlar incelendiğinde ise venöz tromboembolizm oluşum riskinin ölümcül kanama riskine üstünlüğünün hastaya spesifik belirlenmesi gerektiği vurgulanmaktadır. Prognostik venöz tromboembolizm ile ilişkili faktörler venöz tromboembolizm oluşum riskini belirlemede ve tromboprofilaksi tedavisine başlamada yardımcı olmaktadır. Venöz tromboembolizm oluşum riski yüksek ve kanama riski düşük olan palyatif bakım hastalarına farmakolojik tromboprofilaksi tedavisi önerilmektedir. Düşük molekül ağırlıklı heparin başta olmak üzere hastadaki risk faktörleri değerlendirilerek standart heparin, fondaparinuks, varfarin, aspirin ve yeni nesil oral antikoagülanlar tromboprofilaksi tedavisi olarak tercih edilmektedir.
Anahtar Kelimeler: Palyatif bakım; venöz tromboembolizm; kaynak kılavuzu
Palliative care aims to improve the quality of life of patients and their families facing difficulties related to life-threatening physical, psychological, social or mental illnesses. Palliative care patients should be tracked to identify the risk of venous thromboembolism (VTE) as they consist of a patient population with advanced age, decreased mobility and comorbidities, including cancer. Thromboprophylaxis is used to reduce the risk of VTE. However, identifying patients who should receive thromboprophylaxis and determining diagnosis, treatment processes and duration of VTE treatment involve certain challenges regarding managing VTE for palliative care patients. The currently available guidelines for managing VTE are primarily for oncology patients and there are, unfortunately, a limited number of guidelines for palliative care patients. This study aims to emphasize the necessity of thromboprophylaxis treatment and determine the agents that should be used for patients with a potential to be hospitalized in palliative care centers by reviewing the existing guidelines. When the guidelines are examined, it is emphasized that the superiority of the risk of formation of VTE over the risk of fatal bleeding should be determined specifically for the patient. Factors associated with prognostic VTE are helpful in determining the risk of VTE and initiating thromboprophylaxis treatment. Pharmacological thromboprophylaxis treatment is recommended for palliative care patients with a high risk of VTE and a low risk of bleeding. By evaluating the risk factors in the patient, especially low molecular weight heparin, standard heparin, fondaparinux, warfarin, aspirin and new generation oral anticoagulants are preferred as thromboprophylaxis treatment.
Keywords: Palliative care; venous thromboembolism; resource guide
- WHO [Internet]. © 2023 WHO [Cited: February 23, 2023]. Palliative care. Available from: [Link]
- Zabrocka E, Wojtukiewicz MZ, Sierko E. Thromboprophylaxis in cancer patients in hospice. Adv Clin Exp Med. 2018;27(2):283-9. [Crossref] [PubMed]
- White C, Noble SIR, Watson M, Swan F, Allgar VL, Napier E, et al. Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study. Lancet Haematol. 2019;6(2):e79-e88. Erratum in: Lancet Haematol. 2019;6(6):e294. [Crossref] [PubMed] [PMC]
- Khoury H, Welner S, Kubin M, Folkerts K, Haas S. Disease burden and unmet needs for prevention of venous thromboembolism in medically ill patients in Europe show underutilisation of preventive therapies. Thromb Haemost. 2011;106(4):600-8. [Crossref] [PubMed]
- Sandset PM, Dahm AEA. Is venous thromboembolism a problem in patients with cancer in palliative care? Lancet Haematol. 2019;6(2):e61-e2. [Crossref] [PubMed]
- Pautex S, Vayne-Bossert P, Jamme S, Herrmann F, Vilarino R, Weber C, et al. Anatomopathological causes of death in patients with advanced cancer: association with the use of anticoagulation and antibiotics at the end of life. J Palliat Med. 2013;16(6):669-74. [Crossref] [PubMed]
- Tardy B, Picard S, Guirimand F, Chapelle C, Danel Delerue M, Celarier T, et al. Bleeding risk of terminally ill patients hospitalized in palliative care units: the RHESO study. J Thromb Haemost. 2017;15(3):420-8. [Crossref] [PubMed]
- Gartner V, Kierner KA, Namjesky A, Kum-Taucher B, Hammerl-Ferrari B, Watzke HH, et al; AUPACS group. Thromboprophylaxis in patients receiving inpatient palliative care: a survey of present practice in Austria. Support Care Cancer. 2012;20(9):2183-7. [Crossref] [PubMed]
- Johnson MJ, McMillan B, Fairhurst C, Gabe R, Ward J, Wiseman J, et al. Primary thromboprophylaxis in hospices: the association between risk of venous thromboembolism and development of symptoms. J Pain Symptom Manage. 2014;48(1):56-64. [Crossref] [PubMed]
- Holmes HM, Bain KT, Zalpour A, Luo R, Bruera E, Goodwin JS. Predictors of anticoagulation in hospice patients with lung cancer. Cancer. 2010;116(20):4817-24. [Crossref] [PubMed] [PMC]
- Ongen G, Yılmaz A, Cirak AK, Ersoy CY, Erden F, Altıntaş F, et al. Venous thromboembolism risk and thromboprophylaxis among hospitalized patients: data from the Turkish arm of the ENDORSE study. Clin Appl Thromb Hemost. 2011;17(5):539-45. [Crossref] [PubMed]
- Güven Platformu. Ulusal Venöz Tromboembolizm Profilaksi ve Tedavi Kılavuzu. İstanbul: Diasan Basım Form Matbacılık; 2010. [Link]
- Türk Toraks Derneği. Venöz tromboembolizm profilaksisi. Pulmoner Tromboembolizm Tanı ve Tedavi Uzlaşı Raporu. 2021. p.106-16. [Link]
- National Guideline Centre (UK). Venous thromboembolism in over 16s: Reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. London: National Institute for Health and Care Excellence (NICE); 2018. [Link]
- Watson HG, Keeling DM, Laffan M, Tait RC, Makris M; British Committee for Standards in Haematology. Guideline on aspects of cancer-related venous thrombosis. Br J Haematol. 2015;170(5):640-8. [Crossref] [PubMed]
- Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous Thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496-520. [Crossref] [PubMed]
- Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927-74. Erratum in: Blood Adv. 2021;5(7):1953. [Crossref] [PubMed] [PMC]
- Streiff MB, Holmstrom B, Angelini D, Ashrani A, Elshoury A, Fanikos J, et al. Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(10):1181-201. [PubMed]
- Queensland Health. Guideline for the Prevention of Venous Thromboembolism (VTE) in Adult Hospitalised Patients. State of Queensland (Queensland Health), December 2018. [Link]
- Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@ esmo.org. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol. 2023;34(5):452-67. [Crossref] [PubMed]
- Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, et al; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334-e7. [PubMed] [PMC]
- Wang TF, Zwicker JI, Ay C, Pabinger I, Falanga A, Antic D, et al. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. J Thromb Haemost. 2019;17(10):1772-8. [Crossref] [PubMed] [PMC]
- Specialist Palliative Care Audit and Guidelines Group (SPAGG). Clinical Guideline for Primary Prophylaxis for Venous Thromboembolism (VTE) in the palliative care setting. 2020. [Link]
- Zabrocka E, Sierko E. Thromboprophylaxis in the end-of-life cancer care: the update. Cancers (Basel). 2020;12(3):600. [Crossref] [PubMed] [PMC]
- Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-7. [Crossref] [PubMed] [PMC]
- Riondino S, Ferroni P, Del Monte G, Formica V, Guadagni F, Roselli M. Venous thromboembolism in cancer patients on simultaneous and palliative care. Cancers (Basel). 2020;12(5):1167. [Crossref] [PubMed] [PMC]
.: Process List